Krystal Biotech, Inc. NMS · KRYS

3 Soaring Stocks That May Have More Upside Ahead

The Motley Fool · 13d ago

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

The Motley Fool · 33d ago

Krystal Biotech to Present at Upcoming Scientific Conferences

GlobeNewswire Inc. · 82d ago

Is Vertex Pharmaceuticals' Empire in Trouble?

The Motley Fool · 95d ago

What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment

The Motley Fool · 126d ago

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

The Motley Fool · 148d ago

Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer

The Motley Fool · 152d ago

Soleus Adds a Significant Number of Celcuity Shares

The Motley Fool · 158d ago

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

GlobeNewswire Inc. · 161d ago

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. · 190d ago

Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop

The Motley Fool · 213d ago

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?

The Motley Fool · 229d ago

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet?

The Motley Fool · 229d ago

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

GlobeNewswire Inc. · 237d ago

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

GlobeNewswire Inc. · 309d ago

Quoin (QNRX) Q2 Loss Beats Estimates

The Motley Fool · 347d ago

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

GlobeNewswire Inc. · 362d ago

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

The Motley Fool · 388d ago

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

GlobeNewswire Inc. · 392d ago

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

GlobeNewswire Inc. · 449d ago

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

GlobeNewswire Inc. · 553d ago

Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight

GlobeNewswire Inc. · 578d ago

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

GlobeNewswire Inc. · 580d ago

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

Benzinga · 651d ago

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

Benzinga · 664d ago